Share on StockTwits

Equities research analysts at FBR Capital Markets assumed coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued to investors on Wednesday. The firm set a “market perform” rating on the stock.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 1.12% during mid-day trading on Wednesday, hitting $21.14. The stock had a trading volume of 319,262 shares. AMAG Pharmaceuticals has a one year low of $16.49 and a one year high of $28.42. The stock’s 50-day moving average is $19.67 and its 200-day moving average is $19.48. The company’s market cap is $464.2 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.02. The company had revenue of $24.80 million for the quarter, compared to the consensus estimate of $23.40 million. During the same quarter last year, the company posted ($0.09) earnings per share. AMAG Pharmaceuticals’s revenue was up 26.3% compared to the same quarter last year. Analysts expect that AMAG Pharmaceuticals will post $-0.60 EPS for the current fiscal year.

Separately, analysts at Zacks upgraded shares of AMAG Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Thursday, July 31st. They now have a $20.00 price target on the stock. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $23.75.

AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.